Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
A phase 2 trial of Pembrolizumab, Doxorubicin, Vinblastine in hodgkin lymphoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Overview
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) is a phase 2 interventional study registered as NCT03407144 by Merck Sharp & Dohme LLC, with 340 participants planned, started 2018-04-09 and due to reach its primary completion in 2026-11-06. Interventions recorded: pembrolizumab, doxorubicin, vinblastine, dacarbazine, cyclophosphamide. Conditions listed: Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Shares Dacarbazine, Vinblastine, Doxorubicin, Hodgkin lymphoma.
- TrialStudy of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
Shares Cyclophosphamide, Doxorubicin, Merck & Co. (MSD), Pembrolizumab.
- TrialA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituxi
Shares Vincristine, Cyclophosphamide, Doxorubicin, Merck & Co. (MSD).
- TrialA Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Th
Shares Vincristine, Cyclophosphamide, Doxorubicin, Hodgkin lymphoma.
- TrialA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Shares Cyclophosphamide, Doxorubicin, Merck & Co. (MSD), Pembrolizumab.
- TrialA Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Shares Hodgkin lymphoma, Merck & Co. (MSD), Pembrolizumab.
- TrialClinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma
Shares Vincristine, Cyclophosphamide, Doxorubicin, Hodgkin lymphoma.
- TrialStudy of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Shares Cyclophosphamide, Doxorubicin, Merck & Co. (MSD), Pembrolizumab.